Systemic Therapy of Onychomycosis

  • Bárður SigurgeirssonEmail author


Onychomycosis should be considered a medical problem, rather than a cosmetic one. In most cases, except the mildest one and in children systemic treatment is needed. Choice of treatment is based on several factors such as the organism isolated, type of onychomycosis, concomitant disorders and possibility of drug interactions. Terbinafine is the drug of choice in patients with dermatophyte onychomycosis. Patients with negative prognostic factors can be more difficult to treat and may need modification of the treatment such as surgery and/or booster treatment. When patients have been cured, it is important to prevent recurrences.


Onychomycosis Treatment Systemic Terbinafine Fluconazole Itraconazole Prognostic factors Recurrence Prevention Surgery Dermatophytes Yeasts Molds Dermatophytoma Matrix involvement Drug interactions Risk factors 

Supplementary material

978-3-319-65649-6_12_MOESM1_ESM.pdf (29 kb)
Patient Handout (PDF 28 kb)


  1. 1.
    Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol. 1994;130(Suppl 43):15.PubMedGoogle Scholar
  2. 2.
    Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol. 1999;12(Suppl 1):S6–9; discussion S17.PubMedGoogle Scholar
  3. 3.
    Szepietowski JC, Reich A, for the National Quality of Life in Dermatology Group. Stigmatisation in onychomycosis patients: a population-based study. Mycoses. 2009;52(4):343–9.PubMedGoogle Scholar
  4. 4.
    Reich A, Szepietowski JC. Health-related quality of life in patients with nail disorders. Am J Clin Dermatol. 2011;12(5):313–20.PubMedGoogle Scholar
  5. 5.
    Roujeau J-C, Sigurgeirsson B, Korting H-C, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004;209(4):301–7.PubMedGoogle Scholar
  6. 6.
    Björnsdóttir S, Gottfredsson M, Thórisdóttir AS, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis. 2005;41(10):1416–22.PubMedGoogle Scholar
  7. 7.
    Arenas R, Domínguez-Cherit J, Fernández LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol. 1995;34(2):138–43.PubMedGoogle Scholar
  8. 8.
    Bonifaz A, Paredes V, Fierro L. Onychocryptosis as consequence of effective treatment of dermatophytic onychomycosis. J Eur Acad Dermatol Venereol. 2007;21(5):699–700.PubMedGoogle Scholar
  9. 9.
    Connelley LK, Dinehart SM, McDonald R. Onychocryptosis associated with the treatment of onychomycosis. J Am Podiatr Med Assoc. 1999;89(8):424–6.PubMedGoogle Scholar
  10. 10.
    Milobratović D, Janković S, Vukičević J, Marinković J, Janković J, Railić Z. Quality of life in patients with toenail onychomycosis. Mycoses. 2013;56:543–51.PubMedGoogle Scholar
  11. 11.
    Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol. 1999;41(2 Pt 1):189–96.PubMedGoogle Scholar
  12. 12.
    Wise F, Sulzberger MB. Urticaria and hay-fever due to trichophytin (Epidermophyton interdigitale). J Am Med Assoc. 1930;95(20):1504.Google Scholar
  13. 13.
    Weary PE, Guerrant JL. Chronic urticaria in association with dermatophytosis. Response to the administration of griseofulvin. Arch Dermatol. 1967;95(4):400–1.PubMedGoogle Scholar
  14. 14.
    Platts-Mills TA, Fiocco GP, Pollart S, Hayden ML, Jackson S, Wilkins SR. Trichophyton allergy in a 24-year-old man with “intrinsic” asthma. Ann Allergy. 1986;56(6):454–5. 70-1.PubMedGoogle Scholar
  15. 15.
    Gumowski P, Lech B, Chaves I, Girard JP. Chronic asthma and rhinitis due to Candida albicans, epidermophyton, and trichophyton. Ann Allergy. 1987;59(1):48–51.PubMedGoogle Scholar
  16. 16.
    Ward GW, Karlsson G, Rose G, Platts-Mills TA. Trichophyton asthma: sensitisation of bronchi and upper airways to dermatophyte antigen. Lancet. 1989;1(8643):859–62.PubMedGoogle Scholar
  17. 17.
    Kivity S, Schwarz Y, Fireman E. The association of perennial rhinitis with Trichophyton infection. Clin Exp Allergy. 1992;22(4):498–500.PubMedGoogle Scholar
  18. 18.
    Ward GW, Woodfolk JA, Hayden ML, Jackson S, Platts-Mills TA. Treatment of late-onset asthma with fluconazole. J Allergy Clin Immunol. 1999;104(3 Pt 1):541–6.PubMedGoogle Scholar
  19. 19.
    Klein PA, Clark RA, Nicol NH. Acute infection with Trichophyton rubrum associated with flares of atopic dermatitis. Cutis. 1999;63(3):171–2.PubMedGoogle Scholar
  20. 20.
    Wilson BB, Deuell B, Mills TA. Atopic dermatitis associated with dermatophyte infection and Trichophyton hypersensitivity. Cutis. 1993;51(3):191–2.PubMedGoogle Scholar
  21. 21.
    Woodfolk JA. Allergy and dermatophytes. Clin Microbiol Rev. 2005;18(1):30–43.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Baran R, Hay RJ, Garduno JI. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat. 2008;19(2):72–81.PubMedGoogle Scholar
  23. 23.
    de Sá DC, Lamas APB, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2013;15:17–36.Google Scholar
  24. 24.
    Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol. 2007;56(6):939–44.PubMedGoogle Scholar
  25. 25.
    Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988;1(2):187–217.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(Suppl 1):67–87.PubMedGoogle Scholar
  27. 27.
    Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet. 2001;40(6):441–72.PubMedGoogle Scholar
  28. 28.
    Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol. 1988;18(2 Pt 1):263–8.PubMedGoogle Scholar
  29. 29.
    Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed – an investigation in onychomycosis. Clin Exp Dermatol. 1991;16(5):374–6.PubMedGoogle Scholar
  30. 30.
    De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol. 1996;132(1):34–41.PubMedGoogle Scholar
  31. 31.
    Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol. 1994;30(6):911–33; quiz 34–6.PubMedGoogle Scholar
  32. 32.
    Janssen-Cilag. Sporanox – summary of product characteristics (last revision 23/04/2013). 2013.Google Scholar
  33. 33.
    Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy. Ann Pharmacother. 1992;26(4):502–9.PubMedGoogle Scholar
  34. 34.
    Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37(3):310–44.PubMedGoogle Scholar
  35. 35.
    Chang C-H, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120(9):791–8.PubMedGoogle Scholar
  36. 36.
    Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005;1(4):299–306.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766–7.PubMedGoogle Scholar
  38. 38.
    Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EGV. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138(3):353–7.PubMedGoogle Scholar
  39. 39.
    Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999;318(7190):1031–5.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. Br J Dermatol. 1999;141(Suppl 56):5–14.PubMedGoogle Scholar
  41. 41.
    Arca E, Taştan HB, Akar A, Kurumlu Z, Gür AR. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatolog Treat. 2002;13(1):3–9.PubMedGoogle Scholar
  42. 42.
    Arenas R, Fernández G, Domínguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol. 1991;30(8):586–9.PubMedGoogle Scholar
  43. 43.
    Bonifaz A, Carrasco-Gerard E, Saúl A. Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol. 1997;36(1):70–2.PubMedGoogle Scholar
  44. 44.
    Bräutigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ. 1995;311(7010):919–22.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Chen J, Liao W, Wen H, Wu J, Yao Z. A comparison among four regimens of itraconazole treatment in onychomycosis. Mycoses. 1999;42(1–2):93–6.PubMedGoogle Scholar
  46. 46.
    De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38(5 Pt 3):S57–63.PubMedGoogle Scholar
  47. 47.
    Degreef H, del Palacio A, Mygind S, Ginter G, Pinto Soares A, Zuluaga de Cadena A. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol. 1999;79(3):221–3.PubMedGoogle Scholar
  48. 48.
    Elewski BE, Scher RK, Aly R, et al. Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis. 1997;59(4):217–20.PubMedGoogle Scholar
  49. 49.
    Haneke E, Tajerbashi M, De Doncker P, Heremans A. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. Dermatology. 1998;196(3):323–9.PubMedGoogle Scholar
  50. 50.
    Havu V, Brandt H, Heikkilä H, et al. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. Br J Dermatol. 1999;140(1):96–101.PubMedGoogle Scholar
  51. 51.
    Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol. 1997;136(2):230–4.PubMedGoogle Scholar
  52. 52.
    Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother. 1992;29(2):195–205.PubMedGoogle Scholar
  53. 53.
    Odom RB, Aly R, Scher RK, et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol. 1997;36(2 Pt 1):231–5.PubMedGoogle Scholar
  54. 54.
    Odom R, Daniel CR, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol. 1996;35(1):110–1.PubMedGoogle Scholar
  55. 55.
    Tang WY, Chong LY, Leung CY, Ho HH, Wong TW. Intermittent pulse therapy with itraconazole for onychomycosis. Experience in Hong Kong Chinese. Mycoses. 2000;43(1–2):35–9.PubMedGoogle Scholar
  56. 56.
    Wang DL, Wang AP, Li RY, Wang R. Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Dermatology. 1999;199(1):47–9.PubMedGoogle Scholar
  57. 57.
    Heikkilä H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol. 2002;146(2):250–3.PubMedGoogle Scholar
  58. 58.
    Hiruma M, Matsushita A, Kobayashi M, Ogawa H. One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis. Evaluation of treatment results according to patient background. Mycoses. 2001;44(3–4):87–93.PubMedGoogle Scholar
  59. 59.
    Bahadir S, Inalöz HS, Alpay K, Agaoglu C, Cimsit G, Parlat P. Continuous terbinafine or pulse itraconazole: a comparative study on onychomycosis. J Eur Acad Dermatol Venereol. 2000;14(5):422–3.PubMedGoogle Scholar
  60. 60.
    Haneke E, Abeck D, Ring J. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. Mycoses. 1998;41(11–12):521–7.PubMedGoogle Scholar
  61. 61.
    Ginter G, De Doncker P. An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. Mycoses. 1998;41(5–6):235–8.PubMedGoogle Scholar
  62. 62.
    Wu J, Wen H, Liao W. Small-dose itraconazole pulse therapy in the treatment of onychomycosis. Mycoses. 1997;40(9–10):397–400.PubMedGoogle Scholar
  63. 63.
    Heikkilä H, Stubb S. Long-term results of patients with onychomycosis treated with itraconazole. Acta Derm Venereol. 1997;77(1):70–1.PubMedGoogle Scholar
  64. 64.
    Jones HE, Zaias N. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol. 1996;35(8):589–90.PubMedGoogle Scholar
  65. 65.
    De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day – a double-blind comparative trial. Br J Dermatol. 1996;134(Suppl 46):16–7; discussion 38.PubMedGoogle Scholar
  66. 66.
    De Doncker P, Van Lint J, Dockx P, Roseeuw D. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis. 1995;56(3):180–3.PubMedGoogle Scholar
  67. 67.
    Walsøe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis. Open and double-blind studies. Acta Derm Venereol. 1990;70(2):137–40.PubMedGoogle Scholar
  68. 68.
    Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150(3):537–44.PubMedGoogle Scholar
  69. 69.
    Ryder NS. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrob Agents Chemother. 1985;27(2):252–6.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Ryder NS, Dupont MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes. Biochem J. 1985;230(3):765–70.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl 39):2–7.PubMedGoogle Scholar
  72. 72.
    Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother. 1997;8:275–88.Google Scholar
  73. 73.
    Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother. 1987;31(9):1365–8.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Rinaldi MG. In vitro susceptibility of dermatophytes to antifungal drugs. Int J Dermatol. 1993;32(7):502–3.PubMedGoogle Scholar
  75. 75.
    Chiritescu MM, Chiritescu ME, Scher RK. Newer systemic antifungal drugs for the treatment of onychomycosis. Clin Podiatr Med Surg. 1996;13(4):741–58.PubMedGoogle Scholar
  76. 76.
    Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails? Arch Dermatol. 1995;131(8):937–42.PubMedGoogle Scholar
  77. 77.
    Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol. 1993;73(4):305–9.PubMedGoogle Scholar
  78. 78.
    Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic treatment for onychomycoses. Br J Dermatol. 1990;123(4):481–6.PubMedGoogle Scholar
  79. 79.
    Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992;43(2):259–84.PubMedGoogle Scholar
  80. 80.
    Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol. 1998;38(5 Pt 3):S37–41.PubMedGoogle Scholar
  81. 81.
    Schatz F, Bräutigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol. 1995;20(5):377–83.PubMedGoogle Scholar
  82. 82.
    Novartis pharma. Lamisil – summary of product characteristics (last revision 21.05.2013). 2013.Google Scholar
  83. 83.
    Katz HI, Gupta AK. Oral antifungal drug interactions. Dermatol Clin. 1997;15(3):535–44.PubMedGoogle Scholar
  84. 84.
    Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatolog Treat. 2008;19(3):168–75.PubMedGoogle Scholar
  85. 85.
    Hall M, Monka C, Krupp P, O’Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213–9.PubMedGoogle Scholar
  86. 86.
    Bangsgaard N, Saunte DM, Folkenberg M, Zachariae C. Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venereol. 2011;91(3):358–9.PubMedGoogle Scholar
  87. 87.
    Kanzler MH. Reevaluating the need for laboratory testing in the treatment of onychomycosis: safety and cost-effectiveness considerations. JAMA Dermatol. 2015:1–2.Google Scholar
  88. 88.
    Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–23.PubMedGoogle Scholar
  89. 89.
    Baran R, Belaich S, Beylot C, et al. Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatol Treat. 1997;8(2):93–7.Google Scholar
  90. 90.
    Billstein S, Kianifard F, Justice A. Terbinafine vs. placebo for onychomycosis in black patients. Int J Dermatol. 1999;38(5):377–9.PubMedGoogle Scholar
  91. 91.
    Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997;37(5 Pt 1):740–5.PubMedGoogle Scholar
  92. 92.
    Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol. 1995;32(5 Pt 1):750–3.PubMedGoogle Scholar
  93. 93.
    Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ. 1992;304(6835):1151–4.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Hofmann H, Bräutigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol. 1995;131(8):919–22.PubMedGoogle Scholar
  95. 95.
    Kejda J. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgrad Med. 1999; Spec No: 12–5.Google Scholar
  96. 96.
    Warshaw EM, Carver SM, Zielke GR, Ahmed DD. Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial. Arch Dermatol. 2001;137(9):1253.PubMedGoogle Scholar
  97. 97.
    van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol. 1992;126(Suppl 39):36–9.PubMedGoogle Scholar
  98. 98.
    Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol. 1996;34(4):595–600.PubMedGoogle Scholar
  99. 99.
    Tausch I, Bräutigam M, Weidinger G, Jones TC. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol. 1997;136(5):737–42.PubMedGoogle Scholar
  100. 100.
    Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months’ follow-up. Acta Derm Venereol. 1997;77(1):66–9.PubMedGoogle Scholar
  101. 101.
    Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis. A multicenter trial of various treatment durations. J Am Podiatr Med Assoc. 2001;91(3):127–31.PubMedGoogle Scholar
  102. 102.
    Sigurgeirsson B, Elewski BE, Rich PA, et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat. 2006;17(1):38–44.PubMedGoogle Scholar
  103. 103.
    Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol. 2002;147(1):118–21.PubMedGoogle Scholar
  104. 104.
    Trivedi NA, Shah PC. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis. Indian J Dermatol. 2010;55(2):198–9.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Honeyman J, Talarico FS, Arruda L, et al. Itraconazole versus terbinafine (LAMISILR): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol. 1997;9(3):215–21.Google Scholar
  106. 106.
    Havu V, Heikkilä H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol. 2000;142(1):97–102.PubMedGoogle Scholar
  107. 107.
    Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):S77–86.PubMedGoogle Scholar
  108. 108.
    Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol. 2010;28(2):151–9.PubMedGoogle Scholar
  109. 109.
    Elewski BE. Once-weekly fluconazole in the treatment of onychomycosis: introduction. J Am Acad Dermatol. 1998;38(6 Pt 2):S73–6.PubMedGoogle Scholar
  110. 110.
    Ling MR, Swinyer LJ, Jarratt MT, et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):S95–102.PubMedGoogle Scholar
  111. 111.
    Drake L, Babel D, Stewart DM, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38(6 Pt 2):S87–94.PubMedGoogle Scholar
  112. 112.
    Scher RK, Daniel R. Nails diagnosis, therapy, surgery. Oxford: Elsevier Saunders; 2005.Google Scholar
  113. 113.
    Rich P, Scher RK, Breneman D, et al. Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):S103–9.PubMedGoogle Scholar
  114. 114.
    Laufen H, Zimmermann T, Yeates RA, Schumacher T, Wildfeuer A. The uptake of fluconazole in finger and toe nails. Int J Clin Pharmacol Ther. 1999;37(7):352–60.PubMedGoogle Scholar
  115. 115.
    Savin RC, Drake L, Babel D, et al. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38(6 Pt 2):S110–6.PubMedGoogle Scholar
  116. 116.
    Barchiesi F, Silvestri C, Arzeni D, et al. In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. Med Mycol. 2009;47(3):321–6.PubMedGoogle Scholar
  117. 117.
    Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366–77.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis. Ann Pharmacother. 2009;43(10):1684–91.PubMedGoogle Scholar
  119. 119.
    Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38(5 Pt 1):702–4.PubMedGoogle Scholar
  120. 120.
    Chen X, Hiruma M, Shiraki Y, Ogawa H. Combination therapy of once-weekly fluconazole (100, 150, or 300 mg) with topical application of ketoconazole cream in the treatment of onychomycosis. Jpn J Infect Dis. 2004;57(6):260–3.PubMedGoogle Scholar
  121. 121.
    Gupta AK, Gregurek-Novak T, Konnikov N, Lynde CW, Hofstader S, Summerbell RC. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J Cutan Med Surg. 2001;5(3):206–10.PubMedGoogle Scholar
  122. 122.
    Montero-Gei F, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol. 1996;35(8):587–8.PubMedGoogle Scholar
  123. 123.
    Gupta AK, Drummond-Main C, Paquet M. Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. J Dermatolog Treat. 2012;24:75–80.PubMedGoogle Scholar
  124. 124.
    Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol. 2013;69:416–25.PubMedGoogle Scholar
  125. 125.
    Barchiesi F, Arzeni D, Camiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol. 2001;39(11):4208–9.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166(2):389–98.PubMedGoogle Scholar
  127. 127.
    Warrilow AGS, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014;58(12):7121–7.PubMedPubMedCentralGoogle Scholar
  128. 128.
    Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2005;53(4):578–84.PubMedGoogle Scholar
  129. 129.
    Darkes MJM, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol. 2003;4(1):39–65.PubMedGoogle Scholar
  130. 130.
    Sigurgeirsson B, Paul C, Curran D, Evans EGV. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol. 2002;147(6):1241–3.PubMedGoogle Scholar
  131. 131.
    Tuccori M, Bresci F, Guidi B, Blandizzi C, Del Tacca M, Di Paolo M. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. Ann Pharmacother. 2008;42(7):1112–7.PubMedGoogle Scholar
  132. 132.
    Doncker PD, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol. 1997;37(6):969–74.PubMedGoogle Scholar
  133. 133.
    Bruch-Gerharz D, Ruzicka T. Dermatomykosen im Kindesalter. Monatsschr Kinderheilkd. 2008;156(2):132–8.Google Scholar
  134. 134.
    Irvine A, Hoeger P, Yan AC. Harper’s textbook of pediatric dermatology. Chichester/Hoboken: Wiley-Blackwell; 2011.Google Scholar
  135. 135.
    Baran R, Hay R, Haneke E, Tosti A. Onychomycosis. The current approach to diagnosis and therapy. 2nd ed. Abingdon: Informa healthcare; 2006.Google Scholar
  136. 136.
    Gupta AK, Chang P, Del Rosso JQ, Adam P, Hofstader SL. Onychomycosis in children: prevalence and management. Pediatr Dermatol. 1998;15(6):464–71.PubMedGoogle Scholar
  137. 137.
    Sigurgeirsson B. Onychomycosis. In: Ólafsson JH, Hay RJ, editors. Antibiotic and antifungal therapies in dermatology. Switzerland: Springer; 2016.Google Scholar
  138. 138.
    Baranov AF, Konopikhina TA, Uglova SV. Combined treatment of onychomycoses with griseofulvin in combination with topical therapy. Vestn Dermatol Venerol. 1966;40(1):46–9.PubMedGoogle Scholar
  139. 139.
    Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol. 2003;149(Suppl 65):15–8.PubMedGoogle Scholar
  140. 140.
    Lauharanta J, Zaug M, Polak A, Reinel D. Combination of amorolfine with griseofulvin: in vitro activity and clinical results in onychomycosis. JAMA SEA. 1993;9(Suppl 4):23–7.Google Scholar
  141. 141.
    Baran R, Feuilhade M, Combernale P, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol. 2000;142(6):1177–83.PubMedGoogle Scholar
  142. 142.
    Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010;24(8):910–5.PubMedGoogle Scholar
  143. 143.
    Jaiswal A, Sharma RP, Garg AP. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2007;73(6):393–6.PubMedGoogle Scholar
  144. 144.
    Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157(1):149–57.PubMedGoogle Scholar
  145. 145.
    Rigopoulos D, Katoulis AC, Ioannides D, et al. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol. 2003;149(1):151–6.PubMedGoogle Scholar
  146. 146.
    Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol. 2001;145(Suppl 60):21–6.PubMedGoogle Scholar
  147. 147.
    Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol. 2001;145(Suppl 60):15–9.PubMedGoogle Scholar
  148. 148.
    Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat. 2005;16(5–6):327–30.PubMedGoogle Scholar
  149. 149.
    Gupta AK, Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol. 2005;4(4):481–5.PubMedGoogle Scholar
  150. 150.
    Sergeev AY, Sergeev YV. Pulsed combination therapy: a new option for onychomycosis. Mycoses. 2001;44(Suppl 1):68–9.Google Scholar
  151. 151.
    Gupta S, Jangra RS, Gupta S, Mahendra A, Kumar A. A painless, minimally invasive technique for debulking onychomycotic nails. J Am Acad Dermatol. 2017;76(1):e17–e9.PubMedGoogle Scholar
  152. 152.
    Zhou BR, Lu Y, Permatasari F, et al. The efficacy of fractional carbon dioxide (CO2) laser combined with luliconazole 1% cream for the treatment of onychomycosis: a randomized, controlled trial. Medicine (Baltimore). 2016;95(44):e5141.Google Scholar
  153. 153.
    Ellis DH, Marley JE, Watson AB, Williams TG. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology. 1997;194(Suppl 1):40–2.PubMedGoogle Scholar
  154. 154.
    English MP. Nails and fungi. Br J Dermatol. 1976;94(6):697–701.PubMedGoogle Scholar
  155. 155.
    Tosti A, Piraccini BM, Stinchi C, Lorenzi S. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol. 1996;135(5):799–802.PubMedGoogle Scholar
  156. 156.
    Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol. 1994;130(Suppl 43):16–21.PubMedGoogle Scholar
  157. 157.
    Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology. 2004;209(2):104–10.PubMedGoogle Scholar
  158. 158.
    Tseng SS, Longley BJ, Scher RK, Treiber RK. Fusarium fingernail infection responsive to fluconazole intermittent therapy. Cutis. 2000;65(6):352–4.PubMedGoogle Scholar
  159. 159.
    Daniel CR, Daniel MP, Daniel CM, Sullivan S, Ellis G. Chronic paronychia and onycholysis: a thirteen-year experience. Cutis. 1996;58(6):397–401.PubMedGoogle Scholar
  160. 160.
    Daniel CR, Daniel MP, Daniel J, Sullivan S, Bell FE. Managing simple chronic paronychia and onycholysis with ciclopirox 0.77% and an irritant-avoidance regimen. Cutis. 2004;73(1):81–5.PubMedGoogle Scholar
  161. 161.
    Seebacher C. Fungal flora of diseased and healthy toenails. Mykosen. 1968;11(12):893–902.PubMedGoogle Scholar
  162. 162.
    Daniel CR, Gupta AK, Daniel MP, Sullivan S. Candida infection of the nail: role of Candida as a primary or secondary pathogen. Int J Dermatol. 1998;37(12):904–7.PubMedGoogle Scholar
  163. 163.
    Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4):S70–80.PubMedGoogle Scholar
  164. 164.
    Elewski BE, Ghannoum MA, Mayser P, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol. 2011.Google Scholar
  165. 165.
    Baran R, de Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol. 1996;76(1):82–3.PubMedGoogle Scholar
  166. 166.
    Sigurgeirsson B. Prognostic factors for cure following treatment of onychomycosis. J Eur Acad Dermatol Venereol. 2010;24(6):679–84.PubMedGoogle Scholar
  167. 167.
    Gupta AK, Konnikov N, Lynde CW, et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. Eur J Dermatol. 1999;9(8):633–8.PubMedGoogle Scholar
  168. 168.
    Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(Suppl 65):5–9.PubMedGoogle Scholar
  169. 169.
    Roberts DT, Evans EG. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol. 1998;138(1):189–90.PubMedGoogle Scholar
  170. 170.
    Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R, Taskforce on Onychomycosis Education. Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):25–33.PubMedGoogle Scholar
  171. 171.
    Carney C, Tosti A, Daniel R, et al. A new classification system for grading the severity of onychomycosis: onychomycosis severity index. 159. Prognostic factors. Arch Dermatol. 2011;147(11):1277–82.PubMedGoogle Scholar
  172. 172.
    Gupta AK, Daniel CR. Factors that may affect the response of onychomycosis to oral antifungal therapy. Australas J Dermatol. 1998;39(4):222–4.PubMedGoogle Scholar
  173. 173.
    Geyer AS, Onumah N, Uyttendaele H, Scher RK. Modulation of linear nail growth to treat diseases of the nail. J Am Acad Dermatol. 2004;50(2):229–34.PubMedGoogle Scholar
  174. 174.
    Zheng Y, Wu Y, Chen H, Zhu Z, Liu L, Zeng J. Analysis of the factors influencing the therapeutic effects of onychomycosis. J Tongji Med Univ. 2001;21(3):259–62.PubMedGoogle Scholar
  175. 175.
    Reszke R, Pełka D, Walasek A, Machaj Z, Reich A. Skin disorders in elderly subjects. Int J Dermatol. 2015;54:e332–8.PubMedGoogle Scholar
  176. 176.
    Baran R. The nail in the elderly. Clin Dermatol. 2011;29(1):54–60.PubMedGoogle Scholar
  177. 177.
    Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2 Pt 1):244–8.PubMedGoogle Scholar
  178. 178.
    Cozzani E, Agnoletti AF, Speziari S, et al. Epidemiological study of onychomycosis in older adults with onychodystrophy. Geriatr Gerontol Int. 2015;16:486.PubMedGoogle Scholar
  179. 179.
    Fiallo P, Cardo PP. Age as limiting factor of the efficacy of itraconazole for treatment of onychomycosis. Mycoses. 2001;44(5):191–4.PubMedGoogle Scholar
  180. 180.
    Elewski BE, Tosti A. Risk factors and comorbidities for onychomycosis: implications for treatment with topical therapy. J Clin Aesthet Dermatol. 2015;8(11):38–42.PubMedPubMedCentralGoogle Scholar
  181. 181.
    Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133(5):699–703.PubMedGoogle Scholar
  182. 182.
    Veer P, Patwardhan NS, Damle AS. Study of onychomycosis: prevailing fungi and pattern of infection. Indian J Med Microbiol. 2007;25(1):53–6.PubMedGoogle Scholar
  183. 183.
    Sergeev AY, Gupta AK, Sergeev YV. The Scoring Clinical Index for Onychomycosis (SCIO index). Skin Therapy Lett. 2002;7(Suppl 1):6–7.PubMedGoogle Scholar
  184. 184.
    Shuster S, Baran R. Recurrence of fungal nail disease and the dissociation of relapse from re-infection. Acta Derm Venereol. 2001;81(2):154–5.PubMedGoogle Scholar
  185. 185.
    Yin Z, Xu J, Luo D. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. J Dermatolog Treat. 2012;23(6):449–52.PubMedGoogle Scholar
  186. 186.
    Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology. 1998;197(2):162–6.PubMedGoogle Scholar
  187. 187.
    Ko JY, Lee HE, Jae H, Oh DH, Kim JS, Yu HJ. Cure rate, duration required for complete cure and recurrence rate of onychomycosis according to clinical factors in Korean patients. Mycoses. 2011;54(5):e384–8.PubMedGoogle Scholar
  188. 188.
    Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol. 2010;62(3):411–4.PubMedGoogle Scholar
  189. 189.
    Elewski BE, Rich P, Tosti A, et al. Onchomycosis: an overview. J Drugs Dermatol. 2013;12(7):s96–s103.PubMedGoogle Scholar
  190. 190.
    Sigurgeirsson B, Steingrímsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol. 2004;18(1):48–51.PubMedGoogle Scholar
  191. 191.
    Ajello L, Getz ME. Recovery of dermatophytes from shoes and shower stalls. J Invest Dermatol. 1954;22(1):17–21; discussion, -4.PubMedGoogle Scholar
  192. 192.
    Broughton RH. Reinfection from socks and shoes in tinea pedis. Br J Dermatol. 1955;67(7):249–54.PubMedGoogle Scholar
  193. 193.
    Ghannoum MA, Isham N, Long L. Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device. J Am Podiatr Med Assoc. 2012;102(4):309–13.PubMedGoogle Scholar
  194. 194.
    Feuilhade de Chauvin M. A study on the decontamination of insoles colonized by Trichophyton rubrum: effect of terbinafine spray powder 1% and terbinafine spray solution 1%. J Eur Acad Dermatol Venereol. 2012;26(7):875–8.PubMedGoogle Scholar
  195. 195.
    Hammer TR, Mucha H, Hoefer D. Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation. Mycopathologia. 2011;171(1):43–9.PubMedGoogle Scholar
  196. 196.
    Amichai B, Grunwald MH, Davidovici B, Farhi R, Shemer A. The effect of domestic laundry processes on fungal contamination of socks. Int J Dermatol. 2013;52:1392–4.PubMedGoogle Scholar
  197. 197.
    Gudnadóttir G, Hilmarsdóttir I, Sigurgeirsson B. Onychomycosis in Icelandic swimmers. Acta Derm Venereol. 1999;79(5):376–7.PubMedGoogle Scholar
  198. 198.
    Hilmarsdottir I, Haraldsson H, Sigurdardottir A, Sigurgeirsson B. Dermatophytes in a swimming pool facility: difference in dermatophyte load in men’s and women’s dressing rooms. Acta Derm Venereol. 2005;85(3):267–8.PubMedGoogle Scholar
  199. 199.
    Daniel CR, Jellinek NJ. Commentary: the illusory tinea unguium cure. J Am Acad Dermatol. 2010;62(3):415–7.PubMedGoogle Scholar
  200. 200.
    Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada – a multicenter survey of 2001 patients. Int J Dermatol. 1997;36(10):783–7.PubMedGoogle Scholar
  201. 201.
    Sigurgeirsson B, Steingrímsson O, Sveinsdóttir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol. 2002;82(6):467–9.PubMedGoogle Scholar
  202. 202.
    Chiacchio ND, Suarez MV, Madeira CL, Loureiro WR. An observational and descriptive study of the epidemiology of and therapeutic approach to onychomycosis in dermatology offices in Brazil. An Bras Dermatol. 2013;88(Suppl 1):3–11.PubMedGoogle Scholar
  203. 203.
    Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014;28(11):1480–91. Epub 2013 Nov 28.PubMedGoogle Scholar
  204. 204.
    Buxton PK, Milne LJ, Prescott RJ, Proudfoot MC, Stuart FM. The prevalence of dermatophyte infection in well-controlled diabetics and the response to Trichophyton antigen. Br J Dermatol. 1996;134(5):900–3.PubMedGoogle Scholar
  205. 205.
    Al-Mutairi N, Eassa BI, Al-Rqobah DA. Clinical and mycologic characteristics of onychomycosis in diabetic patients. Acta Dermatovenerol Croat. 2010;18(2):84–91.PubMedGoogle Scholar
  206. 206.
    Gulcan A, Gulcan E, Oksuz S, Sahin I, Kaya D. Prevalence of toenail onychomycosis in patients with type 2 diabetes mellitus and evaluation of risk factors. J Am Podiatr Med Assoc. 2011;101(1):49–54.PubMedGoogle Scholar
  207. 207.
    Leelavathi M, Azimah MN, Kharuddin NF, Tzar MN. Prevalence of toenail onychomycosis among diabetics at a primary care facility in Malaysia. Southeast Asian J Trop Med Public Health. 2013;44(3):479–83.PubMedGoogle Scholar
  208. 208.
    Gupta AK, Lynde CW, Jain HC, et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol. 1997;136(5):786–9.PubMedGoogle Scholar
  209. 209.
    Güleç AT, Demirbilek M, Seçkin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol. 2003;49(2):187–92.PubMedGoogle Scholar
  210. 210.
    Moreno-Coutiño G, Arenas R, Reyes-Terán G. Clinical presentation of onychomycosis in hiv/aids: a review of 280 mexican cases. Indian J Dermatol. 2011;56(1):120–1.PubMedPubMedCentralGoogle Scholar
  211. 211.
    Gregory N. Special patient populations: onychomycosis in the HIV-positive patient. J Am Acad Dermatol. 1996;35(3 Pt 2):S13–6.PubMedGoogle Scholar
  212. 212.
    Rodwell GEJ, Bayles CL, Towersey L, Aly R. The prevalence of dermatophyte infection in patients infected with human immunodeficiency virus. Int J Dermatol. 2008;47(4):339–43.PubMedGoogle Scholar
  213. 213.
    Ozkan F, Ozturk P, Ozyurt K, et al. Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis. J Dermatol. 2013;40(2):107–10.PubMedGoogle Scholar
  214. 214.
    Kulac M, Acar M, Karaca S, et al. Venous insufficiency in patients with toenail onychomycosis. J Ultrasound Med. 2005;24(8):1085–9.PubMedGoogle Scholar
  215. 215.
    Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol. 2000;14(6):466–9.PubMedGoogle Scholar
  216. 216.
    English MP. Trichophyton rubrum infection in families. Br Med J. 1957;1(5021):744.PubMedPubMedCentralGoogle Scholar
  217. 217.
    Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, Tavakkol A. Molecular analysis of dermatophytes suggests spread of infection among household members. Cutis. 2013;91(5):237–45.PubMedGoogle Scholar
  218. 218.
    Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol. 1997;36(3 Pt 1):395–402.PubMedGoogle Scholar
  219. 219.
    Zaias N, Tosti A, Rebell G, et al. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol. 1996;34(2 Pt 1):302–4.PubMedGoogle Scholar
  220. 220.
    Pickup TL, Adams BB. Prevalence of tinea pedis in professional and college soccer players versus non-athletes. Clin J Sport Med. 2007;17(1):52–4.PubMedGoogle Scholar
  221. 221.
    Chan MKT, Chong L-Y, Achilles Project Working Group in Hong Kong. A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong. J Am Podiatr Med Assoc. 2002;92(8):450–6.PubMedGoogle Scholar
  222. 222.
    Caputo R, De Boulle K, Del Rosso J, Nowicki R. Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. J Eur Acad Dermatol Venereol. 2001;15(4):312–6.PubMedGoogle Scholar
  223. 223.
    Gazes MI, Zeichner J. Onychomycosis in close quarter living review of the literature. Mycoses. 2013;56:610–3.PubMedGoogle Scholar
  224. 224.
    El Fekih N, Belghith I, Trabelsi S, Skhiri-Aounallah H, Khaled S, Fazaa B. Epidemiological and etiological study of foot mycosis in Tunisia. Actas Dermosifiliogr. 2012;103(6):520–4.PubMedGoogle Scholar
  225. 225.
    Jang KA, Chi DH, Choi JH, Sung KJ, Moon KC, Koh JK. Tinea pedis in Korean children. Int J Dermatol. 2000;39(1):25–7.PubMedGoogle Scholar
  226. 226.
    Fletcher CL, Hay RJ, Smeeton NC. Onychomycosis: the development of a clinical diagnostic aid for toenail disease. Part I. Establishing discriminating historical and clinical features. Br J Dermatol. 2004;150(4):701–5.PubMedGoogle Scholar
  227. 227.
    Walling HW. Subclinical onychomycosis is associated with tinea pedis. Br J Dermatol. 2009;161(4):746–9.PubMedGoogle Scholar
  228. 228.
    Gupta AK, Ryder JE. How to improve cure rates for the management of onychomycosis. Dermatol Clin. 2003;21(3):499–505. vii.PubMedGoogle Scholar
  229. 229.
    Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44(3):485–91.PubMedGoogle Scholar
  230. 230.
    Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol. 1995;33(5 Pt 1):775–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Faculty of Medicine, Department of DermatologyUniversity of IcelandReykjavikIceland

Personalised recommendations